Sarcoidosis: Epidemiology and clinical insights
M Rossides, P Darlington, S Kullberg… - Journal of internal …, 2023 - Wiley Online Library
Sarcoidosis is characterized by noncaseating granulomas which form in almost any part of
the body, primarily in the lungs and/or thoracic lymph nodes. Environmental exposures in …
the body, primarily in the lungs and/or thoracic lymph nodes. Environmental exposures in …
Diagnosis and treatment of pulmonary sarcoidosis: a review
JA Belperio, F Shaikh, FG Abtin, MC Fishbein… - Jama, 2022 - jamanetwork.com
Importance Sarcoidosis is an inflammatory granulomatous disease of unknown cause that
affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any …
affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any …
ERS clinical practice guidelines on treatment of sarcoidosis
RP Baughman, D Valeyre, P Korsten… - European …, 2021 - Eur Respiratory Soc
Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …
risk or to improve quality of life (QoL). The indication for treatment varies depending on …
BTS Clinical Statement on pulmonary sarcoidosis
This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation
and management of pulmonary sarcoidosis, with each section summarised with key clinical …
and management of pulmonary sarcoidosis, with each section summarised with key clinical …
Treatment of sarcoidosis: a multidisciplinary approach
AK Gerke - Frontiers in immunology, 2020 - frontiersin.org
Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …
noncaseating granulomatous inflammation that can cause organ damage and diminished …
Diagnosis and management of sarcoidosis
N Soto-Gomez, JI Peters, AM Nambiar - American family physician, 2016 - aafp.org
Sarcoidosis is a systemic disease of unknown etiology characterized by the presence of
noncaseating granulomas in any organ, most commonly the lungs and intrathoracic lymph …
noncaseating granulomas in any organ, most commonly the lungs and intrathoracic lymph …
Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis …
Multinational evidence-based World Association of Sarcoidosi... : Current Opinion in Pulmonary
Medicine Multinational evidence-based World Association of Sarcoidosis and Other …
Medicine Multinational evidence-based World Association of Sarcoidosis and Other …
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
L Richeldi, F Varone, M Bergna… - European …, 2018 - Eur Respiratory Soc
A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a
progressive-fibrosing phenotype, which is associated with a deterioration in lung function …
progressive-fibrosing phenotype, which is associated with a deterioration in lung function …
New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches
RP Baughman, JC Grutters - The Lancet Respiratory Medicine, 2015 - thelancet.com
About half of patients with sarcoidosis will need systemic therapy for their disease. Oral
glucocorticoids are the standard first-line treatment for sarcoidosis. With time, patients might …
glucocorticoids are the standard first-line treatment for sarcoidosis. With time, patients might …
Refractory sarcoidosis: a review
T El Jammal, Y Jamilloux… - … and clinical risk …, 2020 - Taylor & Francis
Sarcoidosis is a multi-system disease of unknown etiology characterized by granuloma
formation in various organs (especially lung and mediastinohilar lymph nodes). In more than …
formation in various organs (especially lung and mediastinohilar lymph nodes). In more than …